FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2555851805> ?p ?o ?g. }

• W2555851805 endingPage "74" @default.
• W2555851805 startingPage "73" @default.
• W2555851805 abstract "The “2016 Chinese guideline for the management of dyslipidemia in adults” (the new Guide for short) released by Chinese Journal of Cardiology is based on the 2007 “Guide for Dyslipidemia Prevention in Chinese Adults” (the 2007 Hyperlipidemia Guide for short) and is the result of a year's effort and work by a team of specialists.1 The public release of the 2007 Hyperlipidemia Guide has had a positive effect on control and management of hyperlipidemia and atherosclerotic cardiovascular disease (ASCVD). In the past decade, there has been a paradigm shift in international and domestic research and the viewpoints in this field; thus, a new guide for dyslipidemia is imperative. The group of specialists who have formulated the guides, from the 1997 “Recommendations for Dyslipidemia Prevention” to the first dyslipidemia guideline in China, until the formulation of this new Guide, have adhered to three principles. First, they used international guides as a reference with an emphasis on the data and evidence from Chinese research, without blind obedience to foreign guides. Second, they adhered to the public welfare and scientific nature of the guide, with no interference of various business interests. Third, they embody authority, as the formulation process for the guide brought together specialists in the field; scientific democracy was fully upheld, evidence was thoroughly collected and evaluated, and authorization was granted by the Disease Prevention and Control Bureau of the National Health and Family Planning Commission, China. The 2007 Hyperlipidemia Guide was primarily based on results from Chinese epidemiological studies conducted over many years, with the highlight being based on the risk stratification for cardiovascular diseases (including stroke) formulated using our own data; owing to the high incidence of ischemic stroke in China, the weight of hypertension in the risk stratification was increased. Presently, randomized double-blind clinical studies of dyslipidemia interventions focused on ASCVD in China are still limited, the only study is Xuezhikang, a partially purified red yeast rice under controlled pharmaceutical manufacturing conditions, contains a family of naturally occurring statins (monacolins)–most prominently monacolin K, which is identical to the lipid-lowering therapy lovastatin (Mevacor), addressing the secondary prevention of myocardial infarction. Since 2007, an increasing number of domestic and international organizations have been conducting studies on dyslipidemia interventions. Only the HPS-2 THRIVE results reported by a Chinese/European collaborative group have been used for over 12,000 Chinese patients. The new Guide for cholesterol and ASCVD published by the American College of Cardiology (ACC) and the American Heart Association (AHA) at the end of 2013 subverts the American Adult Treatment Panel (ATP) system and recommends the removal of low density lipoprotein cholesterol (LDL-C) and other interventional targets of dyslipidemia. The guide lists 4 categories of patients that require statin treatment and recommends intervention with high doses of a high-potency statin. This led to consistent questioning and opposition by the American National Lipid Association, the European Society of Cardiology, the European Atherosclerosis Society, the International Atherosclerosis Society, and leading Chinese scholars in the field. In the recent years, a series of incorrect viewpoints regarding dyslipidemia intervention and ASCVD prevention driven primarily by business interests, have emerged in China. One example is the growing number of the much-hyped small-scale, short follow-up, exploratory studies in which observations act as substitutes for endpoints. These one-sided exaggerated claims of multiple effects (such as anti-inflammatory effects) outside the primary role of statins in lowering the cholesterol suggest the sequential use of 80 mg atorvastatin during the perioperative period of percutaneous coronary intervention (PCI) and acute coronary syndrome (ACS). More seriously, this misconception is already widely accepted in several country-level hospitals. The Chinese new Guide is clear, raises the banners of public welfare and science, adheres to the characteristic evidence from Chinese studies without following the ACC/AHA, and strictly rejects and resists intervention related to business interests. It does not agree with the recommendations of the ACC/AHA, and clearly adheres to interventional LDL-C target values established by the ASCVD risk stratification. Following extensive discussion and voting, it was recommended that the interventional LDL-C target value for the secondary prevention of ASCVD be lowered from <2.0 mmol/L (80 mg/dl) in 2007 to <1.8 mmol/L (70 mg/dl). Besides, in order to fully uphold scientific democracy, Prof. Zhao Shuiping, the Second Xiangya Hospital of Central South University, was invited to present his opinions about not changing the target value of <2.0 mmol/L (80 mg/dl) in detail.2 The new Guide adheres to the scientific theories and laws about cholesterol known for a hundred years, and rejects one-sided excessive emphasis on the multiple effects of statin intervention. The new Guide is based on Chinese data and evidence, and emphasizes that most Chinese patients do not need and cannot tolerate the high-potency high-dose statin treatment recommended by the ACC/AHA. It clearly indicates that the appropriate unified treatment regimen for Chinese patients is to use low-potency doses of statins, and drug combinations only when needed. The ACS and PCI are not singled out, and the sequential use of high-potency, high doses of statins is not recommended. We congratulate all the authors on the publication of the new Guide, and are grateful to the cardiovascular specialists for their dedication to the project. The publication of the new Guide marks the recognition of a successful historic collaboration with the China Cholesterol Education Program (CCEP). The study, promulgation, and implementation of the new Guide are the mission and responsibility of our group and the CCEP. We hope that after the National Conference on Health and Wellness, the New Guide can mark a new stage in the prevention of ASCVD." @default.
• W2555851805 created "2016-11-30" @default.
• W2555851805 creator A5088226639 @default.
• W2555851805 date "2017-06-01" @default.
• W2555851805 modified "2023-09-26" @default.
• W2555851805 title "New guidelines and evidence for prevention and treatment of dyslipidemia and atherosclerotic cardiovascular disease in China^☆" @default.
• W2555851805 cites W2408802297 @default.
• W2555851805 cites W4292764144 @default.
• W2555851805 doi "https://doi.org/10.1016/j.cdtm.2016.11.001" @default.
• W2555851805 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5627699" @default.
• W2555851805 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29063058" @default.
• W2555851805 hasPublicationYear "2017" @default.
• W2555851805 type Work @default.
• W2555851805 sameAs 2555851805 @default.
• W2555851805 citedByCount "12" @default.
• W2555851805 countsByYear W25558518052018 @default.
• W2555851805 countsByYear W25558518052019 @default.
• W2555851805 countsByYear W25558518052020 @default.
• W2555851805 countsByYear W25558518052022 @default.
• W2555851805 countsByYear W25558518052023 @default.
• W2555851805 crossrefType "journal-article" @default.
• W2555851805 hasAuthorship W2555851805A5088226639 @default.
• W2555851805 hasBestOaLocation W25558518051 @default.
• W2555851805 hasConcept C126322002 @default.
• W2555851805 hasConcept C134018914 @default.
• W2555851805 hasConcept C138816342 @default.
• W2555851805 hasConcept C142724271 @default.
• W2555851805 hasConcept C159110408 @default.
• W2555851805 hasConcept C17744445 @default.
• W2555851805 hasConcept C191935318 @default.
• W2555851805 hasConcept C199539241 @default.
• W2555851805 hasConcept C2778096610 @default.
• W2555851805 hasConcept C2779091943 @default.
• W2555851805 hasConcept C2779134260 @default.
• W2555851805 hasConcept C2780182762 @default.
• W2555851805 hasConcept C512399662 @default.
• W2555851805 hasConcept C555293320 @default.
• W2555851805 hasConcept C71924100 @default.
• W2555851805 hasConceptScore W2555851805C126322002 @default.
• W2555851805 hasConceptScore W2555851805C134018914 @default.
• W2555851805 hasConceptScore W2555851805C138816342 @default.
• W2555851805 hasConceptScore W2555851805C142724271 @default.
• W2555851805 hasConceptScore W2555851805C159110408 @default.
• W2555851805 hasConceptScore W2555851805C17744445 @default.
• W2555851805 hasConceptScore W2555851805C191935318 @default.
• W2555851805 hasConceptScore W2555851805C199539241 @default.
• W2555851805 hasConceptScore W2555851805C2778096610 @default.
• W2555851805 hasConceptScore W2555851805C2779091943 @default.
• W2555851805 hasConceptScore W2555851805C2779134260 @default.
• W2555851805 hasConceptScore W2555851805C2780182762 @default.
• W2555851805 hasConceptScore W2555851805C512399662 @default.
• W2555851805 hasConceptScore W2555851805C555293320 @default.
• W2555851805 hasConceptScore W2555851805C71924100 @default.
• W2555851805 hasIssue "2" @default.
• W2555851805 hasLocation W25558518051 @default.
• W2555851805 hasLocation W25558518052 @default.
• W2555851805 hasLocation W25558518053 @default.
• W2555851805 hasLocation W25558518054 @default.
• W2555851805 hasOpenAccess W2555851805 @default.
• W2555851805 hasPrimaryLocation W25558518051 @default.
• W2555851805 hasRelatedWork W1986489592 @default.
• W2555851805 hasRelatedWork W2082415271 @default.
• W2555851805 hasRelatedWork W2357877701 @default.
• W2555851805 hasRelatedWork W2363789018 @default.
• W2555851805 hasRelatedWork W2380501683 @default.
• W2555851805 hasRelatedWork W2512957884 @default.
• W2555851805 hasRelatedWork W3155199870 @default.
• W2555851805 hasRelatedWork W38111772 @default.
• W2555851805 hasRelatedWork W4249487090 @default.
• W2555851805 hasRelatedWork W4386247604 @default.
• W2555851805 hasVolume "3" @default.
• W2555851805 isParatext "false" @default.
• W2555851805 isRetracted "false" @default.
• W2555851805 magId "2555851805" @default.
• W2555851805 workType "article" @default.